PAYS Paysign, Inc.

BUSINESS SUMMARY

Paysign is a prepaid card processor and program manager focused on three customer verticals:

• Plasma-donor compensation — prepaid cards loaded by plasma-collection centers (CSL Behring, Grifols, others) for donors after each donation
• Pharma patient-affordability programs — cards loaded by pharmaceutical manufacturers for patient-copay assistance and rebate programs
• Government and corporate prepaid programs — niche but growing line

Revenue is transaction processing fees plus card-loading fees plus program-management fees. The business model has high switching costs because pharmaceutical and plasma-collection customers integrate Paysign deeply into their operational workflows.

MARKET OPPORTUNITY

The prepaid-card market for healthcare-vertical use cases is structurally niche:

• Plasma-collection is dominated by 3-4 large operators globally; Paysign has the majority of the US plasma-donor compensation market
• Pharma copay-assistance programs are a large and growing market driven by drug pricing pressure and patient-affordability mandates
• Government and corporate programs are smaller but higher margin

Macro context: the revenue growth of 40% YoY reflects the maturation of pharma-affordability programs combined with continued plasma-donor compensation volume.

REVENUE QUALITY

The economics reflect a vertical-specific payments processor:

• Gross margin 59% — moderate-to-high; reflects the program-management premium over generic payments processing
• Operating margin — TTM positive; the business has historically been profitable
• Revenue $82M TTM — small absolute scale
• P/S ~4.6 — premium for the growth profile and the recurring-revenue characteristics

COMPETITIVE ADVANTAGE

The defensible asset is vertical-specific customer integration depth:

• Plasma-collection-center integrations with multi-year customer relationships and embedded operational workflows
• Pharma-affordability program design expertise that takes years to develop
• Bank-and-network relationships for card-issuance scale at competitive cost

What it is not: a moat against Marqeta (MQ) or Adyen if either decided to enter healthcare-vertical prepaid. Paysign's wedge is depth-of-vertical, not scale.

GROWTH THESIS

Three things have to work:

1. Plasma-donation-volume growth continues. Plasma-derived therapeutics demand is structurally growing globally; donor-compensation volume tracks that.
2. Pharma-affordability-program adoption deepens. Drug-pricing pressure drives more manufacturers to need patient-copay programs; Paysign's design expertise scales with this trend.
3. Government-and-corporate vertical scales to provide additional diversification beyond the two core verticals.

KEY RISKS

Three specific risks:

1. Customer concentration in plasma-collection. A small number of customers represent meaningful revenue share; loss or renegotiation is material at this scale.

2. Drug-pricing-policy reversal. A meaningful US drug-pricing policy shift (e.g., Inflation Reduction Act expansion, Medicare negotiation impact) could compress pharma-affordability program demand if rebates absorb need.

3. Larger-payments-processor entry. Marqeta or another scaled processor entering vertical-specific healthcare prepaid would compress Paysign's price-position.

VERDICT

The 84.6/100 score captures genuine niche-leader economics — profitable, recurring revenue, deep customer integration, structural-tailwind exposure. The premium multiple reflects the moat-quality combined with small-cap-scale.

For investors who want vertical-specific payments-infrastructure exposure with healthcare-tailwind positioning, PAYS is one of few liquid pure-plays. For investors needing scale or diversified end-market exposure, the vertical-concentration is the legitimate concern.

The single metric to watch next is pharma-program revenue percentage of total. Continued growth in this higher-margin line beyond plasma-collection compounds the operating-leverage thesis.